Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse

NCT00003701 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00003701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
April 2, 1999
Completion date
June 15, 2007
Enrollment
490 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, urethral cancer